CONMED (CNMD)
(Real Time Quote from BATS)
$72.74 USD
+1.66 (2.34%)
Updated Apr 19, 2024 01:56 PM ET
3-Hold of 5 3
A Value B Growth B Momentum A VGM
Income Statements
Fiscal Year end for CONMED Corporation falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1,245 | 1,045 | 1,011 | 862 | 955 |
Cost Of Goods | 569 | 474 | 443 | 402 | 430 |
Gross Profit | 676 | 571 | 568 | 460 | 525 |
Selling & Adminstrative & Depr. & Amort Expenses | 556 | 501 | 458 | 414 | 446 |
Income After Depreciation & Amortization | 121 | 70 | 110 | 46 | 79 |
Non-Operating Income | 0 | -112 | -1 | 0 | -5 |
Interest Expense | 40 | 29 | 35 | 44 | 43 |
Pretax Income | 81 | -71 | 73 | 2 | 31 |
Income Taxes | 16 | 10 | 11 | -8 | 3 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 64 | -81 | 63 | 10 | 29 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 64 | -81 | 63 | 10 | 29 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 199 | 144 | 194 | 132 | 163 |
Depreciation & Amortization (Cash Flow) | 78 | 74 | 85 | 86 | 84 |
Income After Depreciation & Amortization | 121 | 70 | 110 | 46 | 79 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 31.55 | 30.04 | 32.22 | 29.46 | 29.50 |
Diluted EPS Before Non-Recurring Items | 3.45 | 2.65 | 3.21 | 2.18 | 2.64 |
Diluted Net EPS (GAAP) | 2.04 | -2.68 | 1.94 | 0.32 | 0.97 |
Fiscal Year end for CONMED Corporation falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 327.05 | 304.58 | 317.65 | 295.47 |
Cost Of Goods | NA | 144.87 | 136.52 | 146.96 | 140.15 |
Gross Profit | NA | 182.18 | 168.06 | 170.69 | 155.32 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 131.99 | 137.76 | 143.27 | 142.62 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 50.19 | 30.30 | 27.42 | 12.70 |
Non-Operating Income | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | NA | 9.50 | 10.02 | 10.00 | 10.26 |
Pretax Income | NA | 40.68 | 20.28 | 17.42 | 2.44 |
Income Taxes | NA | 7.61 | 4.44 | 3.69 | 0.63 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 33.07 | 15.84 | 13.73 | 1.82 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 33.07 | 15.84 | 13.73 | 1.82 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 31.50 | 31.69 | 31.80 | 31.20 |
Diluted EPS Before Non-Recurring Items | NA | 1.06 | 0.90 | 0.83 | 0.66 |
Diluted Net EPS (GAAP) | NA | 1.05 | 0.50 | 0.43 | 0.06 |